Keros Therapeutics (NASDAQ:KROS) Cut to “Hold” at TD Cowen

TD Cowen cut shares of Keros Therapeutics (NASDAQ:KROS) from a buy rating to a hold rating in a report published on Thursday, Marketbeat reports.

Other equities research analysts have also issued reports about the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. William Blair lowered shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research report on Thursday, November 7th. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday. Finally, Wells Fargo & Company increased their price objective on shares of Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $85.67.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $18.83 on Thursday. The firm has a fifty day moving average of $59.11 and a two-hundred day moving average of $52.65. The firm has a market cap of $762.75 million, a P/E ratio of -3.61 and a beta of 1.20. Keros Therapeutics has a 1-year low of $15.67 and a 1-year high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $0.39 million during the quarter. During the same period last year, the business earned ($1.33) EPS. The business’s quarterly revenue was up 4750.0% on a year-over-year basis. On average, sell-side analysts expect that Keros Therapeutics will post -5.26 EPS for the current year.

Institutional Trading of Keros Therapeutics

Several hedge funds have recently added to or reduced their stakes in KROS. KBC Group NV increased its holdings in shares of Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares in the last quarter. Values First Advisors Inc. acquired a new position in Keros Therapeutics during the 3rd quarter valued at about $89,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Keros Therapeutics during the 2nd quarter worth about $128,000. Finally, LMR Partners LLP acquired a new stake in shares of Keros Therapeutics in the 3rd quarter worth approximately $213,000. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.